CoChat

The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis

Open access
Yang, Gong, Rosen, Daniel G., Zhang, Zhihong, Bast, Robert C., Mills, Gordon B., Colacino, Justin A., Mercado-Uribe, Imelda, Liu, Jinsong · 2006 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Epithelial–stromal interactions play a critical role in tumor initiation and progression; cancer-associated stroma, but not normal stroma, is known to be tumor-promoting. However, the molecular signal used by epithelial cancer cells to reprogram normal stroma to a tumorigenic stroma is not known. Here, we present evidence to suggest that the chemokine growth-regulated oncogene 1 (Gro-1) may be one such signaling molecule. We showed that the expression of Gro-1 is activated by RAS and is vital for cell survival and the malignant transformation of ovarian epithelial cells. Surprisingly, we found that Gro-1 is a potent inducer of senescence in stromal fibroblasts and that this effect depends on functional p53. Senescent fibroblasts induced by Gro-1 can promote tumor growth whereas abrogation of senescence through immortalization results in loss of such tumor promoting activity. We also demonstrated that stromal fibroblasts adjacent to epithelial cancer cells are senescent in human ovarian cancer specimens and in heterografts from RAS-transformed human ovarian epithelial cells and ovarian cancer cells. Moreover, Gro-1 was expressed at significantly higher amounts in ovarian cancer than in normal tissues and was higher in serum samples from women with ovarian cancer than in serum from women without ovarian cancer. These findings provide strong evidence that RAS-induced Gro-1 can reprogram the stromal microenvironment through the induction of senescence of fibroblasts and thus can promote tumorigenesis. Therefore, Gro-1 may be a therapeutic target as well as a diagnostic marker in ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0605752103

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 11

  1. AF Olumi, GD Grossfeld, SW Hayward, PR Carroll, TD Tlsty, GR Cunha Cancer Res 59, 5002–5011 (1999).
  2. E Balentien, BE Mufson, RL Shattuck, R Derynck, A Richmond Oncogene 6, 1115–1124 (1991).
  3. IM Shih, M Herlyn In Vivo 8, 113–123 (1994).
  4. G Yang, DG Rosen, I Mercado-Uribe, JA Colacino, GB Mills, RC Bast, C Zhou, J Liu Carcinogenesis, 2006).
  5. SC Mok, DA Bell, RC Knapp, PM Fishbaugh, WR Welch, MG Muto, RS Berkowitz, SW Tsao Cancer Res 53, 1489–1492 (1993).
  6. Y Ichikawa, M Nishida, H Suzuki, S Yoshida, H Tsunoda, T Kubo, K Uchida, M Miwa Cancer Res 54, 33–35 (1994).
  7. 10.1002/(sici)1097-0142(19970415)79:8<1581::aid-cncr21>3.0.co;2-t · doi:10.1002/(sici)1097-0142(19970415)79:8<1581::aid-cncr21>3.0.co;2-t
  8. 10.1002/(sici)1097-0142(19980315)82:6<1088::aid-cncr12>3.0.co;2-2 · doi:10.1002/(sici)1097-0142(19980315)82:6<1088::aid-cncr12>3.0.co;2-2
  9. FT Bosman, A de Bruine, C Flohil, A van der Wurff, J ten Kate, WW Dinjens Int J Dev Biol 37, 203–211 (1993).
  10. A Krtolica, J Campisi Adv Gerontol 11, 109–116 (2003).
  11. BM Kacinski EXS 74, 181–190 (1995).

Cited by

See all 348

Metadata

Authors
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Experimental Therapeutics, and
  • Departments of *Pathology,
Venue
Proceedings of the National Academy of Sciences
Published
2006-10-31
Volume
103
Issue
44
Pages
16472-16477
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1992742879
Cited by
341
References
49
Citations by year
2026: 4 · 2025: 7 · 2024: 19 · 2023: 23 · 2022: 15 · 2021: 12 · 2020: 15 · 2019: 16 · 2018: 19 · 2017: 9 · 2016: 28 · 2015: 26 · 2014: 23 · 2013: 26 · 2012: 12
FWCI
8.86
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
Ras signaling, cellular senescence, stromal fibroblasts, ovarian cancer, stromal-epithelial interactions, cancer-associated stroma, p53, tumor microenvironment, malignant transformation, tumor growth promotion, serum biomarkers, therapeutic target
MeSH terms
Cell Transformation, Neoplastic, Cells, Cultured, Female, Fibroblasts, Gene Expression Regulation, Humans, Ovarian Neoplasms, Signal Transduction, Biomarkers, Tumor Suppressor Protein p53, Cellular Senescence, Stromal Cells, Apoptosis, ras Proteins, Chemokines, CXC, Chemokine CXCL1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. https://app.cochat.ai/papers/10.1073/pnas.0605752103
The paper
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0605752103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.